[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 227,536,400
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 23,190 M
  • EBITDA $ 26,518 M
  • 60-Month Beta 0.77
  • Price/Sales 4.74
  • Price/Cash Flow 10.60
  • Price/Book 6.97

Options Overview Details

View History
  • Implied Volatility 46.28% (-1.91%)
  • Historical Volatility 29.61%
  • IV Percentile 53%
  • IV Rank 37.59%
  • IV High 64.20% on 10/09/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 1) 1.37 (2.65%)
  • Put/Call Vol Ratio 0.74
  • Today's Volume 52,917
  • Volume Avg (30-Day) 46,729
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 1,315,927
  • Open Int (30-Day) 1,333,993
  • Expected Range 50.21 to 52.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.81
  • Number of Estimates 4
  • High Estimate $0.87
  • Low Estimate $0.77
  • Prior Year $0.97
  • Growth Rate Est. (year over year) -16.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.87 +7.75%
on 06/30/26
52.12 -1.03%
on 07/29/26
+3.24 (+6.70%)
since 06/29/26
3-Month
41.00 +25.80%
on 06/08/26
52.12 -1.03%
on 07/29/26
+11.29 (+28.02%)
since 04/29/26
52-Week
35.12 +46.87%
on 03/30/26
64.16 -19.61%
on 01/23/26
-2.36 (-4.38%)
since 07/29/25

Most Recent Stories

More News
Novo Nordisk Sues Eli Lilly Over Obesity Drug Advertising Claims

Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly's advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo's latest...

NVO : 51.58 (+1.22%)
LLY : 1,210.02 (-0.87%)
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END

AVAI : 0.1300 (-16.13%)
TNDM : 18.59 (+4.67%)
NVO : 51.58 (+1.22%)
DXCM : 75.14 (+0.39%)
SNY : 44.85 (-1.52%)
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 167.26 (+4.93%)
CLDX : 37.51 (+5.42%)
PGEN : 5.45 (-1.45%)
NVO : 51.58 (+1.22%)
AKAM : 107.41 (-3.92%)
SNEX : 72.07 (-2.98%)
ORCL : 117.74 (-1.85%)
ABBV : 263.30 (+0.04%)
GDXJ : 94.98 (-1.86%)
RSP : 215.73 (-0.90%)
VKTX : 33.43 (-1.27%)
LLY : 1,210.02 (-0.87%)
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

HIMS : 25.00 (-14.73%)
NVO : 51.58 (+1.22%)
LLY : 1,210.02 (-0.87%)
MSFT Stock Alert: Microsoft Invests $2.5 Billion in AI Implementation Unit

Microsoft shares soar as the behemoth announces a $2.5 billion investment in a new initiative, Microsoft Frontier Co. But does that warrant buying MSFT stock today?

MSFT : 390.54 (-0.71%)
NVO : 51.58 (+1.22%)
UL : 66.00 (-1.30%)
AMZN : 226.65 (-1.82%)
Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk, which makes Ozempic and Wegovy. NVO stock has been moving up, so is it overvalued now?

NVO : 51.58 (+1.22%)
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

TDOC : 9.18 (-1.92%)
NVO : 51.58 (+1.22%)
OZEM : 32.66 (-0.46%)
LLY : 1,210.02 (-0.87%)
DXCM : 75.14 (+0.39%)
OLLI : 71.37 (+3.48%)
These 3 Quality Stocks Will Make You Want to LEAP on Their Calls

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks...

SBUX : 104.14 (+1.01%)
NVO : 51.58 (+1.22%)
LLY : 1,210.02 (-0.87%)
PFE : 25.15 (-0.40%)
AMZN : 226.65 (-1.82%)
DIS : 98.48 (-0.41%)
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

CVS : 105.92 (-3.13%)
CI : 296.47 (-1.52%)
NVO : 51.58 (+1.22%)
LLY : 1,210.02 (-0.87%)
UNH : 420.57 (-1.92%)
5 Best Growth Stocks for the Next 10 Years

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

MELI : 1,863.31 (+0.04%)
AAPL : 338.19 (-0.56%)
AVGO : 370.32 (-2.78%)
NVO : 51.58 (+1.22%)
LLY : 1,210.02 (-0.87%)
NET : 270.38 (+2.38%)
TSM : 374.67 (-4.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 53.35
2nd Resistance Point 52.73
1st Resistance Point 52.16
Last Price 51.58
1st Support Level 50.96
2nd Support Level 50.34
3rd Support Level 49.77

See More

52-Week High 64.16
Fibonacci 61.8% 53.07
Last Price 51.58
Fibonacci 50% 49.64
Fibonacci 38.2% 46.21
52-Week Low 35.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.